^
1d
BCAT1 mediates the carcinogenic effects of environmental bisphenol exposure: mechanistic discoveries in osteosarcoma and pan-cancer analysis. (PubMed, Mol Divers)
All five bisphenols exhibited high binding affinity for BCAT1 in structural simulations, and pan-cancer analysis revealed BCAT1 overexpression in multiple solid tumors, correlating with unfavorable clinical outcomes. Collectively, these findings suggest that bisphenols may act as potential regulators of BCAT1, with implications for tumor progression, though further experimental validation is required to confirm the actual enzymatic activity modulation and carcinogenic effects.
Journal • Pan tumor
|
BCAT1 (Branched Chain Amino Acid Transaminase 1 )
1d
CXCR4 Facilitates Osteosarcoma Progression through MMP9-Mediated Cell Migration and Matrix Degradation. (PubMed, Curr Cancer Drug Targets)
CXCR4 promotes osteosarcoma cell invasiveness through upregulation of MMP9. The CXCR4-MMP9 axis may represent a potential therapeutic target to limit osteosarcoma progression and metastasis.
Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • MMP9 (Matrix metallopeptidase 9)
3d
Tumor-derived sphingosine-1-phosphate shapes angiogenesis in the acidic microenvironment of osteosarcoma via paracrine and autocrine signaling. (PubMed, Front Cell Dev Biol)
S1P signaling was pharmacologically inhibited using the FDA-approved S1P modulator FTY720 (Fingolimod)...These findings identify a previously unrecognized acidosis-S1P axis that contributes to angiogenic remodeling in osteosarcoma. Our results highlight the multifaceted role of S1P in regulating endothelial behavior and suggest that targeting S1P signaling may represent a promising strategy to disrupt pathological neoangiogenesis in osteosarcoma.
Journal
|
TGFB1 (Transforming Growth Factor Beta 1) • ENG (Endoglin)
|
fingolimod
3d
Integrative Multiomics Analysis Identifies a Novel Gene Signature That Predicts Chemotherapy Resistance and Poor Survival in Osteosarcoma. (PubMed, Hum Mutat)
Drug sensitivity predictions confirmed resistance to first-line chemotherapy agents. Collectively, these findings establish a clinically actionable 13-gene biomarker and provide a mechanistic framework linking transcriptional profiles to chemoresistance biology, exposing novel therapeutic vulnerabilities in OS.
Journal • Tumor mutational burden • Gene Signature
|
TMB (Tumor Mutational Burden)
3d
Optimisation of osteosarcoma sample processing for epigenetic analysis: A comparative evaluation of formalin-fixed, paraffin-embedded samples with and without decalcification versus fresh tissue. (PubMed, Rev Esp Patol)
FFPE samples are suitable for epigenetic studies, although performance depends on pre-analytical factors. Frozen tissue remains the gold standard. Nitric acid should be avoided. A protocol is proposed that prioritises frozen tissue, documents decalcification methods, excludes strong acids, incorporates quality control measures, and favours samples less than five years old.
Journal
|
MDM2 (E3 ubiquitin protein ligase)
3d
Sarcomatoid squamous cell carcinoma of the mandible: Radiologic-pathologic correlation and diagnostic pitfalls of an aggressive osteolytic lesion. (PubMed, Radiol Case Rep)
This case highlights the key imaging features of mandibular SSCC and underscores important diagnostic pitfalls related to its non-specific osteolytic presentation. It emphasizes the critical role of multimodal imaging and radiologic-pathologic correlation in differentiating this rare entity from other aggressive mandibular lesions, thereby facilitating timely and appropriate management.
Journal
|
VIM (Vimentin)
5d
Biological evaluation of pH-responsive eugenol-loaded CMC/ZnO-HA nanocomposites for enhanced bone wound healing and osteogenesis. (PubMed, Tissue Cell)
The transcriptional changes were associated with an 84% rise in calcium nodule accumulation, validating the composite's effectiveness in facilitating the progression from cellular commitment to full mineralization. The EUG-CMC/ZnO-HA nanocomposite functions as a sophisticated scaffold for bone wound healing by facilitating regulated medication administration and promoting tissue regeneration.
Journal
|
COL1A1 (Collagen Type I Alpha 1 Chain) • RUNX2 (RUNX Family Transcription Factor 2)
5d
B7-H3 membranous expression correlates with histological grading in a two-center cohort of 133 pre-treatment bone and soft tissue sarcoma samples. (PubMed, BMC Cancer)
B7-H3 is a promising treatment target in sarcomas as it is highly expressed particular in high grade bone and soft tissue sarcomas, such as pleomorphic liposarcomas and osteosarcomas.
Journal
|
CD276 (CD276 Molecule)
5d
A Study of DS-8201a in Children, Adolescents, or Young Adults With recurrent Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor (clinicaltrialsregister.eu)
P1/2, N=55, National Institutes of Health, National Cancer Institute, Division of Cancer Treatment and Diagnosis
New P1/2 trial
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
6d
Lactylation-driven metabolic reprogramming promotes osteosarcoma malignancy via HDGF-mediated proliferation and immune modulation. (PubMed, Front Immunol)
Our study unveils a novel lactylation-HDGF regulatory association that promotes OS progression and modulates the tumor microenvironment. These findings highlight HDGF as a promising prognostic biomarker and therapeutic target, offering new avenues for precision therapy in osteosarcoma.
Journal
|
HDGF (Heparin Binding Growth Factor)
6d
Unconventional activation of the proto-oncogene FGFR1 by extracellular phosphate via H2O2-mediated kinase oxidation. (PubMed, Cell Rep)
The H2O2 burst oxidizes critical cysteine and methionine residues in FGFR1, promoting receptor activation and downstream signaling. These results reveal a targetable oncogenic mechanism for FGFR1 activation and explain the physiological Pi sensing mechanism.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1)
6d
Astrocytic Phenotypic Switching in Posterior Piriform Cortex Orchestrates Bone Cancer Pain-Depression Comorbidity via Purinergic-Noradrenergic Signaling. (PubMed, Adv Sci (Weinh))
Interventions targeting astrocyte phenotypes, including minocycline and Lcn2 knockdown, normalized the posterior piriform cortex neurochemistry and alleviated both nociceptive and affective symptoms. These findings define a mechanistic framework in which astrocytic dysfunction orchestrates pain and depression, and highlight astrocyte-directed strategies for treating cancer pain-depression comorbidity.
Journal
|
ADORA2A (Adenosine A2a Receptor)
|
minocycline